Impairments of long-term potentiation in hippocampal slices of β-amyloid-infused rats

European Journal of Pharmacology

Volumn 382, Issue 3, 1999, Pages 167-175

  Itoh, Akio ^a   Akaike, Tadashi ^a,b   Sokabe, Masahiro ^a   Nitta, Atsumi ^c   Iida, Ryuichi ^a   Olariu, Ana ^a   Yamada, Kiyofumi ^a   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

amyloid protein; Alzheimer's disease; Hippocampus; Learning; Long term potentiation; Memory; Nicotine

Indexed keywords

AMYLOID BETA PROTEIN; BICUCULLINE; HEXAMETHONIUM; NICOTINE; NICOTINIC RECEPTOR;

ALZHEIMER DISEASE; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HIPPOCAMPUS; IN VITRO STUDY; LONG TERM POTENTIATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

AMYLOID BETA-PROTEIN; ANIMALS; ELECTRIC STIMULATION; EVOKED POTENTIALS; HEXAMETHONIUM; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; NICOTINE; PERFUSION; PYRAMIDAL CELLS; RATS; RATS, WISTAR; RECEPTORS, NICOTINIC; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 0032754051     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00601-9     Document Type: Article

References (57)

1. Arispe N., Pollard H.B., Rojas E. Giant multilevel cation channels formed by Alzheimer disease amyloid β-protein [AβP-(1-40)] in bilayer membranes. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10573-10577.
2. Arispe N., Rojas E., Pollard H.B. Alzheimer disease amyloid β protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminium. Proc. Natl. Acad. Sci. U.S.A. 90:1993;567-571.
3. Bierer L.M., Haroutunian V., Gabriel S., Knott P.J., Carlin L.S., Purohit D.P., Perl D.P., Schmeidler J., Kanof P., Davis K.L. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J. Neurochem. 64:1995;749-760.
4. Binsack D.P., Lee H.K., Leonard C.M., Montoya-Zayala M., Marotta C.A. Rats transgenic for human APP770 have impaired place memory and hippocampal long-term potentiation. Neurosci. Abstr. 22:1996;1892.
5. Bliss T.V.P., Collingridge G.L. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
6. Brazell M.P., Mitchell S.N., Joseph M.H., Gray J.A. Acute administration of nicotine increases the in vivo extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid and ascorbic acid preferentially in the nucleus accumbens of the rat: comparison with caudate-putamen. Neuropharmacology. 29:1990;1177-1185.
7. Cai X.D., Golde T., Younkin S. Release of excess amyloid β-protein from a mutant amyloid β-protein precursor. Science. 259:1993;514-516.
8. Chartier-Harlin M.C., Crawford F., Houlden H., Warren A., Hughes D., Fidani L., Goate A., Rossor M., Roques P., Hardy J., Mullan M. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature. 353:1991;844-846.
9. Chesselet M.F. Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis. Neuroscience. 12:1984;347-375.
10. Citron M., Oltersort T., Haass C., McConlogue L., Hung A.Y., Scubert P., Vigo-Pelfrey C., Lieberburg I., Selkoe D.J. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature. 360:1992;672-674.
11. Clarke P.B.S., Pert C.B., Pert A. Autoradiographic distribution of nicotine receptors in rat brain. Brain Res. 323:1984;390-395.
12. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: cortical cholinergic innervation. Science. 219:1983;1184-1190.
13. Cullen W.K., Suh Y.H., Rowan M.J. Block of LTP in rat hippocampus in vivo by β-amyloid precursor protein fragment. NeuroReport. 8:1997;3213-3217.
14. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403.
15. Etcheberrigaray R., Ito E., Oka K., Tofel-Grehl B., Gibson G.E., Alkon D.L. Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8209-8213.
16. + channels. Science. 264:1994;276-279.
17. Frazier C.J., Rollins Y.D., Breese C.R., Leonard S., Freedman R., Dunwiddie T.V. Acetylcholine activates an α-bungarotoxin-sensitive nicotinic current in rat hippocampal interneurons, but not pyramidal cells. J. Neurosci. 18:1998;1187-1195.
18. Freund R.K., Jungschaffer D.A., Collins A.C., Wehner J.M. Evidence for modulation of GABAergic neurotransmission by nicotine. Brain Res. 453:1988;215-220.
19. Freund R.K., Luntz-Leybman V., Collins A.C. Nicotine interferes with GABA-mediated inhibitory processes in mouse hippocampus. Brain Res. 527:1990;286-291.
20. Goate A., Chartier-Harlin M.C., Mullan M., Brown J., Crawford F., Fidani L., Giuffra L., Haynes A., Irving N., James L., Mant R., Newton P., Rooke K., Roques P., Talbot C., Pericak-Vance M., Roses A., Williamson R., Rossor M., Owen M., Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 349:1991;704-749.
21. Gray R., Rajan A.S., Radcliffe K.A., Yakehiro M., Dani J.A. Hippocampal synaptic transmission enhanced by low concentration of nicotine. Nature. 383:1996;713-716.
22. Haas C., Schlossmacher M.G., Hung A.Y., Vigo-Pelfrey C., Mellon A., Ostaszeeski B.L., Lieberburg I., Koo E.H., Schenk D., Teplow D.B., Selkoe D.J. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature. 359:1992;322-325.
23. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Neurosci. 12:1991;383-388.
24. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
25. Hunter B.E., de Fiebre C.M., Papke R.L., Kem W.R., Meyer E.M. A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci. Lett. 168:1994;130-134.
26. Itoh A., Nitta A., Nadai M., Nishimura K., Hirose M., Hasegawa T., Nabeshima T. Dysfunction of cholinergic and dopaminergic neuronal systems in β-amyloid protein-infused rats. J. Neurochem. 66:1996;1113-1117.
27. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against β-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
28. Kosik K.S. Alzheimer plaques and tangles: advances on both fronts. Trends Neurosci. 14:1991;218-219.
29. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., Walz P., Zhang C., Finch C.E., Krafft G.A. Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6448-6453.
30. 3H]aminobutyric acid in rabbit caudate nucleus slices. J. Neurochem. 46:1986;1109-1117.
31. Léna C., Changeux J.P., Mulle C. Evidence for "preterminal" nicotinic receptors on GABAergic axons in the rat interpeduncular nucleus. J. Neurosci. 13:1993;2680-2688.
32. Marczynski T.J. GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease revisited. Brain Res. Bull. 45:1998;341.
33. 2+ homeostasis and cell death. J. Neurosci. 15:1995;6239-6249.
34. 2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16:1993;409-414.
35. McGehee D.S., Heath M.J.S., Gelber S., Devay P., Role L.W. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 269:1995;1692-1696.
36. Murrell J., Farlow M., Ghetti B., Benson M.D. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science. 254:1991;97-99.
37. Nabeshima T. Behavioral aspects of cholinergic transmission: role of basal forebrain cholinergic system in learning and memory. Prog. Brain Res. 98:1993;405-411.
38. Nabeshima T., Nitta A. β-amyloid protein-induced memory impairment and neuronal dysfunction animal model. Tohoku J. Med. 174:1994;241-249.
39. Nalbantoglu J., Tirado-Santlago G., Lahsaïni A., Poirier J., Goncalves O., Verge G., Momoli F., Welner S.A., Massicotte G., Julien J.P., Shapiro M.L. Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein. Nature. 387:1997;500-505.
40. Nitta A., Itoh A., Hasegawa T., Nabeshima T. β-amyloid protein-induced Alzheimer's disease animal model. Neurosci. Lett. 170:1994;63-66.39.
41. Nitta A., Fukuta T., Hasegawa T., Nabeshima T. Continuous infusion of β-amyloid protein into the rat cerebral ventricle induces learning impairment and neuronal and morphological degeneration. Jpn. J. Pharmacol. 73:1997;51-57.
42. Paxinos G., Watson C. The Rat Brain in the Stereotaxic Coordinates. 1986;Academic Press, New York.
43. Pike C.J., Walencewicz A.J., Glaba C.G., Cotman C.W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563:1991;311-314.
44. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16:1993;403-443.
45. Sawada S., Yamamoto C., Ohno-Shosaku T. Long-term potentiation and depression in the dentate gyrus, and effects of nicotine. Neurosci. Res. 20:1994;323-329.
46. Schluz P.E. β-peptide enhance the magnitude and probability of long-term potentiation. Neurosci. Abstr. 22:1996;2111.
47. Selkoe D.J. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17:1994;489-517.
48. Shoji M., Golde T.E., Ghiso J., Cheung T.T., Estus S., Shaffer L.M., Cai X.D., McKay D.M., Tintner R., Frangione B., Younkin S.G. Production of Alzheimer β protein by normal proteolytic processing. Science. 258:1992;126-129.
49. Sims N.R., Bowen D.M., Allen S.J., Smith C.C., Neary D., Thomas D.J., Davison A.N. Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem. 40:1983;503-509.
50. Tanaka T., Yamada K., Senzaki K., Narimatsu H., Nishimura K., Kameyama T., Nabeshima T. NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by β-amyloid protein in rats. Eur. J. Pharmacol. 352:1998;135-142.
51. Waite J., Cole G.M., Frautschy S.A., Connor D.J., Thal L.J. Solvent effects on beta protein toxicity in vivo. Neurobiol. Aging. 13:1992;595-599.
52. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., DeLong M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
53. Wilcock G.K., Esiri M.N., Bowen D.M., Smith C.C. Alzheimer's disease: correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J. Neurol. Sci. 57:1982;407-417.
54. Wonnacott S., Drasdo A., Sanderson E., Rowell P. Presynaptic Nicotinic Receptors and the Modulation of Transmitter Release. Ciba Foundation Symposium. The Biology of Nicotine Dependence. 1990;87-105 Wiley, Chichester.
55. Wu J., Anwyl R., Rowan M.J. β-amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. Eur. J. Pharmacol. 284:1995;R1-R3.
56. Yamada K., Tanaka T., Senzaki K., Kameyama T., Nabeshima T. Propentofylline improves learning and memory deficits induced in rats by β-amyloid protein-(1-40). Eur. J. Pharmacol. 349:1998;15-22.
57. Yankner B.A., Duffy L.K., Kirschner D.D. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science. 250:1990;279-282.